Importance of Collection Tube during Clinical Studies of Oseltamivir
- 1 May 2007
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (5), 1835-1836
- https://doi.org/10.1128/aac.01534-06
Abstract
Ex vivo conversion of the anti-influenza drug oseltamivir to its active metabolite can be inhibited by the esterase inhibitor dichlorvos or by using commercial fluoride-oxalate tubes. Oseltamivir and its active metabolite remain intact in plasma samples during a proposed virus heat inactivation step: incubation at 60°C for 45 min.Keywords
This publication has 11 references indexed in Scilit:
- Rapid Degradation of Oseltamivir Phosphate in Clinical Samples by Plasma EsterasesAntimicrobial Agents and Chemotherapy, 2006
- Antivirals for influenza in healthy adults: systematic reviewThe Lancet, 2006
- Vaccines and Antiviral Drugs in Pandemic PreparednessEmerging Infectious Diseases, 2006
- Oseltamivir Resistance during Treatment of Influenza A (H5N1) InfectionNew England Journal of Medicine, 2005
- Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemicJournal of Antimicrobial Chemotherapy, 2005
- Pharmacokinetics and Dosage Recommendations for an Oseltamivir Oral Suspension for the Treatment of Influenza in ChildrenPediatric Drugs, 2001
- Development of a high-performance liquid chromatographic–mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urineJournal of Chromatography B: Biomedical Sciences and Applications, 2000
- Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802Clinical Pharmacokinetics, 1999
- Disinfection and Inactivation of the Human T Lymphotropic Virus Type III/Lymphadenopathy-Associated VirusThe Journal of Infectious Diseases, 1985
- INACTIVATION OF LYMPHADENOPATHY-ASSOCIATED VIRUS BY HEAT, GAMMA RAYS, AND ULTRAVIOLET LIGHTThe Lancet, 1985